About the book
Acute myeloid leukemia (AML) is the common set acute leukemia in adults, while acute lymphoid leukemia (ALL) is the commonest cancer in childhood. For many years, the diagnosis of "leukemia" has represented a death penalty for our patients. However, in the last decades, tremendous progress has been made, leading to establishing ALL as one of the most curable malignancies (at least as far as the pediatric setting is concerned), to overall save around 50% of adult patients, and to cure without chemotherapy one of the most aggressive AML subtypes, the acute promyelocytic leukemia. Major advances have regarded both biology and, consequently, the treatment of these diseases. Particularly, the discovery of the genetic basis for many leukemia subtypes led to improve our prognostic capability, the possibility to modulate toxicity based on the risk, and eventually novel targeted approaches (eg. tyrosine kinase inhibitors for BCR/ABL1-positive ALL and anti-FLT3 for a subset of AML). Finally, patients' management has significantly benefitted from the improvements in cellular therapies, including stem cell transplantation and, more recently, the adoption of CAR-T cells, especially for ALL.
This book intends to provide the reader with a comprehensive overview of the current state-of-the-art in acute leukemias pathobiology, classification, and treatment, with special emphasis on the most important evidence-based developments.